There are some hardhitters reporting on Wednesday, among them banking titan Lloyds Banking Group (LON:LLOY) and drugs giant GlaxoSmithKline plc (LON:GSK).
Lloyds issues an interim management statement at a time when news flow surrounding UK-listed banks "isn’t improving much", says broker The Share Centre.
In focus will be comment on a potential 'hard' Brexit following the EU referendum in June, suggests the broker.
This would see the UK leaves the single market and therefore may lose passporting rights. The government appears to be learning towards this as a preferred option.
"This will be the first quarter of full post Brexit results for them and management comments will be scrutinised very closely," said the broker.
"Investors should expect to see PPI claims still being a drag while assets and the loan portfolio will still be written off," said The Share Centre, which rates shares a 'hold'.
"The current state of low interest margins will hurt them more while we should expect to see further branch closures," the broker added.
Another sore point, which has disgruntled private investors has been that the government will not now selloff the remainder of the shares to the retail public.
Michelle McGrade, chief investing officer at online stockbroker TD Direct Investing, has urged the government to rethink the exclusion of private investors from the Lloyds share sale.
Last week, speaking to Proactive, McGrade highlighted that Lloyds is a share that individuals are more than happy to buy and hold.
“We’re finding it (Lloyds) is the most traded stock usually … that has been for some considerable time,” she said.
Meanwhile, Deutsche is expecting Lloyds' third quarter update to be relatively quiet, which would come as a relief after a long-running saga of what Lloyds refers to as “conduct provisions” - mis-selling scandals and the like.
It expects margins will have fallen slightly quarter-to-quarter, albeit in line with management guidance, while the movement in the pension deficit “offers the most potential for uncertainty”, though a payment protection insurance charge would not be a surprise.
“We expect market focus to remain firmly the outlook for 2017 and beyond, particularly for margins, which we forecast to deteriorate from mid-2017,” Deutsche said, as it cut its target price to 57p from 59p.
Wednesday also sees interims from GlaxoSmithKline with the figures set to show a solid, if unspectacular, rise in revenues and earnings per share (EPS).
One of the major worries among investors is there aren't enough potential blockbusters flowing from the Glaxo medicines pipeline to replace its best-selling asthma drug Advair, which has lost patent protection
But Investec started covering the shares last week with a 'buy', saying the group offers "lower-risk underlying earnings growth versus peers", driven by leverage across major divisions.
Analyst Andrew Whitney said: "With new products gaining scale, and as the pharma business enters a prolonged period free from major IP expiry, we see the value in GSK’s diversified portfolio becoming better appreciated."
Investec has a price target of 1,925p on the shares - a hefty distance from the current price of around 1,629p.
Significant announcements expected
Interims: GlaxoSmithKline plc (LON:GSK), JZ Capital Partners Ltd (LON:JZCP), Torchmark Corporation (LON:TMK)
Finals: Earthport plc (LON:EPO)
Trading statement: Antofagasta PLC (LON:ANTO), Cobham PLC (LON:COB), Genel Energy PLC (LON:GENL), Lloyds Banking Group PLC (LON:LLOY)